Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/170265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Jianping Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, People's Hospital of Yangzhong, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, People's Hospital of Yangzhong, China.
Zitieren
APA
Wang, J., Zhang, J., Gao, J., Zhao, M., & Ma, Z. (2023). Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/170265
Vancouver
Wang J, Zhang J, Gao J, Zhao M, Ma Z. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/170265
BibTeX
@article{Wang2023,
author = {Wang, Jianping and Zhang, Jian and Gao, Jie and Zhao, Mengmeng and Ma, Zhenkai},
title = {Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/170265}
}
EUVIMED